# Cytokinetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytokinetics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.cytokinetics.com
- Total disclosed funding: $75M
- Latest round: Series C (Nov 27, 2000)
- Investors on record: 8

## About

Cytokinetics, Inc. is a US-based biopharmaceutical company dedicated to developing innovative therapies that enhance muscle function, targeting diseases such as heart failure and various neuromuscular disorders.Founded in 1997 by James Spudich, Cytokinetics, Inc. is headquartered in South San Francisco, US. The company specializes in developing small molecule muscle activators and inhibitors. It has successfully navigated several funding rounds, with the most recent deal occurring on April 29, 2004, raising USD 33.00 mn. The firm has executed a total of 5 deals.Cytokinetics focuses on developing small molecule muscle activators and inhibitors that target diseases related to compromised muscle function. Their product offerings address conditions such as heart failure, hypertrophic cardiomyopathy (HCM), and various neuromuscular diseases. The company primarily serves hospitals and specialty clinics in the US, with plans to expand into European and international markets to reach healthcare professionals involved in muscle-related disease management.In 2024, Cytokinetics reported a revenue of USD 18.47 mn, while also facing an EBITDA of USD -526.72 mn for the same year. The company generates revenue through direct sales and partnerships with pharmaceutical firms, marketing its innovative therapies to healthcare providers.Cytokinetics plans to utilize the funding received from its most recent round to advance the development and commercialization of its Cytometrix platform and drug discovery programs. The company aims to launch new products targeting muscle function disorders within the next few years. Expansion plans include entering additional international markets, focusing on Europe and Asia by 2025, to broaden its reach in the specialty cardiology market.

## Funding rounds

- Series C, Nov 27, 2000, $55M — Alta Partners, GCM Grosvenor, Mayfield Fund, Sevin Rosen Funds, Vulcan, Lombard Odier & Cie
- Series B, Sep 9, 1999, $20M — Mayfield Fund, Sevin Rosen Funds, Vulcan, Duke University, International Biomedicine Holdings

## Investors

- Mayfield Fund (https://capitalatlas.ai/funds/mayfield-fund) — Series B, Series C
- Sevin Rosen Funds (https://capitalatlas.ai/funds/sevin-rosen-funds) — Series B, Series C
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series B, Series C
- Duke University — Series B
- International Biomedicine Holdings — Series B
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C
- GCM Grosvenor — Series C
- Lombard Odier & Cie — Series C